REGINfo: NOVARTIS - Chimie de spécialité - Financial information

SEARCH BY

Issuer directory

KEYWORDS

COMPANIES / ISIN

TYPE OF INFORMATION

INDUSTRY

ADVANCED SEARCH

COMPARTMENTS / INDICES

France

America

Asia

Oceania

> ASX 20
Australia - ASX 20
> NZX 15
New Zealand - NZX 15

Africa

> FTSE/JSE...
South Africa - FTSE/JSE Top 40
> TA 25
Israel - TA 25
- ALONY HETZ
- AZRIELI GROUP
- BAZAN
- BEZEQ
- DELEK DRILLIN
- DELEK GROUP
- DISCOUNT
- ELBIT SYSTEMS
- Energean Oil Gas
- FIBI BANK
- GAZIT GLOBE
- HAREL
- ICL
- IFF
- ISRAEL CORP
- LEUMI
- LivePerson
- MIZRAHI TEFAHOT
- NICE
- OPKO HEALTH
- ORMAT
- PAZ OIL
- PERRIGO
- Phoenix Group Holdings
- POALIM
- SHUFERSAL
- STRAUSS GROUP
- TEVA
- TOWER JAZZ

Europe

COMPANY SEARCH RESULT

$NOVARTIS: Click to view the issuer\'s details$

Last update : 28/01/2011 >View issuer details

2021.10.19 | 07:15 | Permanent Information Releases / General Company News

puce Global Heart Hub and Novartis partner to tackle ASCVD, a global health crisis and world’s #1 killer - HTML (w)

2021.10.11 | 09:15 | Permanent Information Releases / General Company News

puce Sandoz completes acquisition of GSK’s cephalosporin business, reinforcing leading global position in antibiotics - HTML (w)

2021.10.01 | 17:52 | Permanent Information Releases / General Company News

puce Sandoz Resolves Legacy Federal Government Civil Investigation in the U.S. Regarding Generic Drugs - HTML (w)

2021.09.30 | 07:15 | Permanent Information Releases / General Company News

puce Novartis accelerates efforts toward ESG targets to increase access to medicines, improve health equity and achieve net-zero carbon emissions - HTML (w)

2021.09.19 | 13:30 | Permanent Information Releases / General Company News

puce Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer - HTML (w)

2021.09.17 | 13:30 | Permanent Information Releases / General Company News

puce Novartis announces findings from a real-world study of alpelisib demonstrating clinical benefit in people with PIK3CA-Related Overgrowth Spectrum (PROS) - HTML (w)

2021.09.17 | 00:05 | Permanent Information Releases / General Company News

puce Novartis reports positive health-related quality of life data for 177Lu-PSMA-617 radioligand therapy in patients with advanced prostate cancer at ESMO 2021 - HTML (w)

2021.09.08 | 13:30 | Permanent Information Releases / General Company News

puce Sandoz strengthens pipeline by entering into agreement for biosimilar bevacizumab, a key oncology medicine - HTML (w)

2021.09.01 | 01:01 | Permanent Information Releases / General Company News

puce World-first agreement between Novartis and the NHS enables broad and rapid access to first-in-class cholesterol-lowering medicine Leqvio® ?(inclisiran) - HTML (w)

2021.08.30 | 07:15 | Permanent Information Releases / Sales and Revenues

puce Novartis presents important overall survival and quality-of-life results across solid tumor portfolio, among other key data at ESMO - HTML (w)

2021.08.24 | 07:15 | Permanent Information Releases / General Company News

puce Novartis provides update on BELINDA study investigating Kymriah® as second-line treatment in aggressive B-cell non-Hodgkin lymphoma - HTML (w)

2021.08.03 | 07:15 | Permanent Information Releases / General Company News

puce Novartis announces lift of partial clinical trial hold and plans to initiate a new, pivotal Phase 3 study of intrathecal OAV-101 in older patients with SMA - HTML (w)

2021.07.21 | 07:00 | Permanent Information Releases / General Company News

puce Novartis hat im zweiten Quartal dank der Dynamik wichtiger Wachstums-marken eine starke Performance erzielt; Prognose für 2021 unverändert - HTML (w)

2021.07.21 | 07:00 | Permanent Information Releases / General Company News

puce Novartis delivered strong Q2 performance, driven by momentum of key growth brands. FY 2021 guidance unchanged. - HTML (w)

2021.07.21 | 07:00 | Permanent Information Releases / General Company News

puce Novartis: forte performance au deuxième trimestre, soutenue par la dynamique des marques clés de croissance; prévisions pour l’exercice 2021 inchangées - HTML (w)

Pages : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10 / Doc nb : 1438